Neonatal jaundice is among the most common findings in the newborn period — and most of the time it is physiologic and self-limited. But a subset of infants have cholestasis, defined biochemically and pathophysiologically distinct from unconjugated hyperbilirubinemia, and the consequences of missing it are severe. Biliary atresia, the most common surgically correctable cause of cholestasis, is exquisitely time-sensitive: Kasai hepatoportoenterostomy (HPE) success rates exceed 70% before 60 days of age and fall below 25% after 90 days. The USA median age at HPE remains 63 days — well beyond the optimal window.
This article is a resident-targeted reference that walks through bilirubin metabolism, the recognition of pathologic jaundice, the GGT-guided differential diagnosis of cholestasis, the major surgical and medical etiologies (biliary atresia, PFIC, Alagille syndrome, alpha-1-antitrypsin deficiency, bile acid synthesis defects, PNAC), and a step-wise diagnostic and management algorithm. It is based on the NASPGHAN/ESPGHAN 2017 guideline, SIGENP 2022 position paper, Feldman & Sokol NeoReviews 2021, and the AAP 2022 hyperbilirubinemia guideline.
⚡
The single most important pearl in this entire article: Any jaundiced infant still icteric at 2 weeks of age (term) or 3 weeks (preterm) must have fractionated bilirubin measured. A conjugated (direct) bilirubin > 1 mg/dL — or > 20% of total when total bilirubin > 5 — is never physiologic and warrants immediate workup and pediatric GI/hepatology referral.
1. Bilirubin Metabolism — Why Neonates Get Jaundiced
Bilirubin is produced from heme released during senescent red-cell breakdown by macrophages in the reticuloendothelial system. Unconjugated (indirect) bilirubin is lipid-soluble, bound to albumin in plasma, and cannot be excreted in urine — but it can cross the blood-brain barrier, which is the basis for kernicterus risk. In the hepatocyte, the enzyme UGT (uridine 5′-diphospho-glucuronosyltransferase) conjugates bilirubin with glucuronic acid, rendering it water-soluble. Conjugated (direct) bilirubin is then excreted via bile into the duodenum, deconjugated by intestinal flora to urobilinogen, and either excreted in stool (giving stool its brown colour) or reabsorbed via the enterohepatic circulation.
💡
Key pearl — why newborns get jaundiced: Newborns produce 2–3× more bilirubin per kg than adults because fetal haemoglobin has a shorter lifespan (60–90 days vs. adult 120 days), and the neonatal UGT enzyme is only ~1% of adult activity. The result is a physiologic unconjugated hyperbilirubinemia that peaks at days 3–5 in term infants. Conjugated hyperbilirubinemia is never physiologic.
2. Physiologic vs Pathologic Jaundice
Physiologic jaundice — what is normal?
Onset
After 24 hours of age
Duration
< 2 weeks (term) · < 3 weeks (preterm)
Bilirubin type
Unconjugated ONLY — always
Stool / urine
Normal yellow-green stool · light yellow urine
Mechanism
Immature UGT + high RBC turnover + enterohepatic recirculation
Action
Monitor with AAP nomogram; phototherapy only if threshold reached
🏆
Never assess bilirubin by visual inspection alone. Studies show clinicians differ by 13–15 mg/dL from measured values. Always measure TSB or TcB.
Pathologic jaundice — red flags to act on
Any one of the following should prompt immediate fractionation of bilirubin:
🚨 Jaundice in the first 24 hours — always pathologic (hemolysis, infection, metabolic disease).
🚨 Jaundice > 2 weeks (term) or > 3 weeks (preterm) — must rule out cholestasis; fractionate now.
🚨 Conjugated bilirubin > 1 mg/dL (or > 20% of total when total > 5) — cholestasis; never normal.
🚨 Acholic (clay-coloured) stools — strongest sign of biliary obstruction; suspect biliary atresia.
🚨 Dark/brown urine — conjugated bilirubin in urine = cholestasis.
🚨 TSB rising rapidly (> 0.3 mg/dL/hr in first 24h; > 0.2 mg/dL/hr after) — suggests hemolysis.
🚨 Hepatomegaly or splenomegaly — liver disease, storage disorders, portal hypertension.
🚨 Signs of acute encephalopathy — high-pitched cry, opisthotonus, lethargy → emergency.
3. Neonatal Cholestasis — Definition & Epidemiology
📋
Definition (NASPGHAN/ESPGHAN 2017): Conjugated (direct) bilirubin > 1 mg/dL when total bilirubin is < 5 mg/dL — OR — conjugated component > 20% of total bilirubin when total > 5 mg/dL. Occurs in the first year of life (usually within the first 3 months). Never physiologic.
Preterm infants on PN > 2 weeks
10–20%
Cholestasis caused by biliary atresia
25–40%
Caused by monogenic genetic disorders
~25%
⏰
Why timing matters: Kasai HPE success is > 70% if performed before 60 days, but drops to < 25% after 90 days. The USA median age at HPE is 63 days. Early recognition of cholestasis saves native livers.
Key history clues
👨👩👧
Family history: consanguinity → AR disease; siblings with neonatal cholestasis → PFIC, ALGS, A1AT.
🤰
Maternal history: cholestasis of pregnancy → mother may be PFIC carrier; acute fatty liver of pregnancy → consider LCHAD deficiency in infant.
🦠
Maternal infections: TORCH (Toxoplasma, Rubella, CMV, HSV, Syphilis) during pregnancy → congenital infection.
👶
Gestational age: prematurity → PNAC risk; SGA → increased cholestasis risk.
💧
Parenteral nutrition: PN > 2 weeks → PNAC; soy-based lipid emulsion significantly increases risk.
🧪
Newborn screen: review for galactosemia, hypothyroidism, tyrosinemia, cystic fibrosis — all treatable.
🟫
Stool & urine color: acholic stools or dark urine = biliary obstruction. Serial monitoring is essential.
🕗
Delayed meconium: consider CF, hypothyroidism.
🤢
GI symptoms: diarrhea → PFIC1 (FIC1 deficiency); vomiting + lethargy + poor feeding → metabolic disease or sepsis.
Physical exam — high-yield findings
⭐
Stool color (most critical): acholic/clay-colored = biliary obstruction. Must directly observe stool — parents and clinicians often misidentify pale stools as normal.
🟤
Hepatomegaly: firm, enlarged liver strongly suggests biliary atresia. Firmness indicates fibrosis. Measure in cm below RCM.
🟣
Splenomegaly (early): think storage disease (Niemann-Pick, Gaucher) or hemolytic disorders — not portal hypertension at this age.
👁️
Posterior embryotoxon: Alagille syndrome — slit-lamp required. Present in 43% of ALGS patients.
💓
Heart murmur: peripheral pulmonic stenosis → Alagille; other congenital cardiac defects → biliary atresia (BASM).
🦴
Butterfly vertebrae: Alagille — on spine XR. Present in ~39%.
😊
Triangular facies / dysmorphic features: Alagille, Zellweger, chromosomal disorders.
👀
Cataracts: galactosemia, congenital infections (CMV, rubella), Zellweger spectrum.
💤
Hypotonia: mitochondrial disease, peroxisomal (Zellweger), IEM.
⚠️
Neurologic signs (irritability, lethargy, seizures): sepsis, ICH, metabolic/mitochondrial disease, panhypopituitarism.
4. Differential Diagnosis
Surgical (extrahepatic) causes — exclude urgently
Biliary atresia (BA)
35–40%
Progressive sclerosing destruction of extrahepatic bile ducts. Most common surgically correctable cause. Kasai HPE curative if done early.
Choledochal malformation / cyst
~5%
Dilatation of biliary tract ± pancreatico-biliary maljunction. Diagnosed by fasting ultrasound. Surgery mandatory — malignant transformation risk if untreated.
Neonatal sclerosing cholangitis (NSC)
Rare
High GGT (often > 800 IU/L). Pruning of small bile ducts on IOC. Associated with DCDC2 mutations (ciliopathy). Differentiate from BA via IOC.
Cholelithiasis / inspissated bile
< 2%
Gallstones or thick bile plugging the CBD. US diagnosis. Treated with biliary irrigation.
Spontaneous perforation of CBD
Rare
Bile ascites. Echogenic fluid on US. Surgical drainage required.
Medical (intrahepatic) causes
Genetic / metabolic
PFIC types 1–6 (ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, MYO5B); Alagille syndrome (JAG1, NOTCH2); alpha-1-antitrypsin deficiency (SERPINA1); bile acid synthesis defects (CYP7B1, AKR1D1, HSD3B7…); citrin deficiency, galactosemia, tyrosinemia type 1; mitochondrial / peroxisomal (Zellweger); CDG, urea cycle defects, FAO defects.
Endocrine
Panhypopituitarism (cholestasis resolves with hormone replacement); hypothyroidism (check newborn screen + TSH/free T4); adrenal insufficiency.
Infectious
CMV (most common congenital infection, 1–2% of births); HSV, parvovirus B19, enterovirus, adenovirus, rubella; congenital syphilis (rising in US); UTI / sepsis (urine culture in ALL); toxoplasmosis, listeria.
Immune / hematologic
Gestational alloimmune liver disease (GALD, formerly NH); HLH; congenital lupus; post-hemolytic cholestasis (ABO/Rh).
Toxic / secondary
PN-associated cholestasis (PNAC); intestinal failure–associated liver disease (IFALD); perinatal asphyxia; cardiovascular/circulatory disorders; idiopathic transient neonatal cholestasis.
5. GGT-Guided Diagnostic Approach
Once cholestasis is confirmed, serum GGT — combined with total serum bile acids — guides the next steps. Three patterns predominate:
HIGH GGT
> 200–300 U/L
Biliary atresia (exclude FIRST), choledochal cyst, neonatal sclerosing cholangitis, alpha-1-antitrypsin deficiency, Alagille syndrome, cystic fibrosis, PFIC type 3 (MDR3/ABCB4).
LOW / NORMAL GGT
PFIC 1 (ATP8B1 / FIC1), PFIC 2 (ABCB11 / BSEP), PFIC 4 (TJP2), PFIC 5 (NR1H4 / FXR), PFIC 6 (MYO5B), USP53 deficiency, ARC syndrome, BAAT/BACL conjugation defects, GALD (also low GGT), endocrinopathies.
LOW / NORMAL GGT + LOW SERUM BILE ACIDS
(< 125 µmol/L in cholestasis — paradoxical)
Bile acid synthesis defects: 3β-HSD-oxidoreductase (HSD3B7), Δ⁴-3-oxosteroid 5β-reductase (AKR1D1), oxysterol 7α-hydroxylase (CYP7B1), 2-methylacyl-CoA racemase (AMACR), cerebrotendinous xanthomatosis. Diagnose by urine bile acid mass spectrometry. Treat with oral cholic acid — excellent response!
Laboratory patterns & associated diagnoses
| Lab finding |
Associated diagnoses |
Key confirmatory test |
| GGT > 300 U/L | BA, NSC, A1AT, Alagille, CF, PFIC3, PNAC | US + IOC, sweat Cl⁻, A1AT Pi phenotype |
| Low/normal GGT + cholestasis | PFIC 1, 2, 5 (FXR), MYO5B, TJP2, ARC, GALD | Gene panel, BSEP immunostaining, serum bile acids |
| Elevated AFP | PFIC 2 (ABCB11), tyrosinemia type 1, citrin deficiency | Urine succinylacetone, SLC25A13 gene |
| High ferritin + coagulopathy | GALD, HLH | Buccal biopsy / MRI (GALD); NK cell activity, fibrinogen (HLH) |
| Hyperammonemia + cholestasis | Urea cycle defects, citrin, OTC deficiency | Plasma amino acids, urine orotic acid |
| Lactic acidosis + cholestasis | Mitochondrial respiratory chain defects, FAO defects | Lactate:pyruvate ratio, acylcarnitine profile, mtDNA |
| Elevated VLCFA | Zellweger spectrum (peroxisomal), MEDNIK | Plasma VLCFA, phytanic acid, erythrocyte plasmalogens |
6. Biliary Atresia — Classification, Diagnosis & Kasai HPE
Classification by anatomy
Type 1
~5%
Atresia of common bile duct only. Mildest form. Intrahepatic ducts patent. Best surgical outcome.
Type 2a
~2%
Atresia of common hepatic duct. Gallbladder, cystic, and CBD may be preserved.
Type 2b
~2%
Atresia to junction of cystic duct. All extrahepatic ducts atretic except gallbladder ± cystic duct.
Type 3
~93%
Complete atresia to porta hepatis. All extrahepatic ducts obliterated. Requires Kasai HPE immediately.
⚠️
BA with splenic malformation (BASM) — present in ~20% of all BA cases: polysplenia/asplenia, situs inversus, preduodenal portal vein, cardiac defects, laterality defects.
Diagnostic workup
- Clinical + labs: high GGT, elevated conjugated bilirubin, acholic stools. Use stool color card. Review A1AT phenotype and CF sweat test before surgical exploration — both can mimic BA and false-positive the IOC.
- Fasting abdominal ultrasound: triangular cord sign (85–100% PPV for BA), absent or abnormal gallbladder, non-visualization of CBD, hepatic artery diameter, BASM features. A normal US does NOT rule out BA.
- Liver biopsy: bile duct proliferation, bile plugs, portal edema and fibrosis → 90–95% accurate for BA. Helpful but not definitive. Early biopsies (< 4–6 weeks) may be non-specific; A1AT and ALGS can mimic BA histologically.
- Intraoperative cholangiogram (IOC) = GOLD STANDARD. Non-visualization of patent extrahepatic biliary tree confirms BA. Performed laparoscopically or at open surgery. If BA confirmed → proceed immediately to Kasai HPE in the same operation.
🆕
Emerging biomarker — serum MMP-7: 95–98% sensitivity, 83–95% specificity for BA. May enable early non-invasive identification. Not yet in standard clinical use — no standardized cutoffs.
Kasai HPE — outcomes by age at surgery
🌟75–90% 10-year transplant-free survival if TB < 2 mg/dL at 3 months post-HPE.
📉~20% 3-year transplant-free survival if TB > 6 mg/dL at 3 months post-HPE.
🏥70–80% of all BA patients ultimately require liver transplantation.
⏰63 days — USA median age at Kasai, well beyond the optimal window.
Post-Kasai complications to monitor
🦠 Recurrent cholangitis — prophylactic antibiotics are standard of care.
💊 Fat-soluble vitamin deficiency (A, D, E, K) — supplement and monitor levels.
🩸 Portal hypertension and esophageal varices — surveillance endoscopy as indicated.
🎗️ Hepatocellular carcinoma — screen with AFP and imaging.
📉 Growth failure — optimize MCT-containing nutrition.
7. Progressive Familial Intrahepatic Cholestasis (PFIC)
An autosomal-recessive group of disorders caused by mutations in canalicular transport genes. PFIC types 1, 2, 4, 5, and 6 have low/normal GGT; PFIC 3 (MDR3/ABCB4) has high GGT.
PFIC 1 · ATP8B1 (FIC1)
Low / Normal
Diarrhea, pancreatitis, hearing loss. Multisystem (FIC1 also expressed in intestine). No HCC risk.
PFIC 2 · ABCB11 (BSEP)
Low / Normal
High AFP. Highest HCC risk among PFIC types — monitor closely.
PFIC 3 · ABCB4 (MDR3)
HIGH
Milder pruritus than PFIC 1/2. Often responds well to UDCA alone. Older age of onset possible. Low HCC risk.
PFIC 4 · TJP2
Low / Normal
Tight junction defect → disrupted canalicular structure. Early-onset severe cholestasis. No HCC risk.
PFIC 5 · NR1H4 (FXR)
Low / Normal
High AFP. Rapid progression to end-stage disease. Undetectable hepatic BSEP expression. HCC risk.
PFIC 6 · MYO5B
Low / Normal
Associated with microvillous inclusion disease (MVID). Normal GGT cholestasis. No HCC risk.
🔬
Why PFIC 3 has HIGH GGT and the others don't: GGT secretion into bile requires phospholipids. PFIC 3 (MDR3/ABCB4 defect) means phospholipids are absent from bile, leaving pure bile acids that act as detergents and injure the duct epithelium → ductular damage and GGT spillage. PFIC 1, 2, 4, 5, and 6 disrupt other transporters, so MDR3 is intact, phospholipids are still present in bile, and GGT is not elevated.
PFIC treatment
💊
UDCA 10–30 mg/kg/day — first-line, especially PFIC 3.
💉
IBAT inhibitors: Maralixibat (Alagille), Odevixibat (PFIC 2) — FDA-approved.
🔪
Partial external biliary diversion (PEBD) — PFIC 1, PFIC 2 (before cirrhosis).
🫀
Liver transplantation — advanced disease or uncontrolled pruritus.
8. Alagille Syndrome (ALGS)
Autosomal dominant. JAG1 mutation in 94%; NOTCH2 in 5%. Incidence ~1 in 30,000–70,000. Haploinsufficiency: one mutant allele is enough to cause disease.
Liver (bile duct paucity)
High GGT, elevated bile acids, severe pruritus — often the most disabling symptom. Occasional acholic stool in infancy.
100%
Cardiac
Peripheral pulmonic stenosis (most common), Tetralogy of Fallot, pulmonary atresia.
~88%
Characteristic facies
Broad forehead, deep-set eyes, pointed chin, bulbous nose. Often not recognizable in neonatal period — appears more clearly by 6 months.
79–88%
Butterfly vertebrae
Anterior arch fusion defect on CXR. Usually asymptomatic.
~39%
Posterior embryotoxon
Thickened Schwalbe line — slit-lamp required. Not specific to ALGS alone.
~43%
Renal anomalies
Renal dysplasia, tubulopathy.
~22%
Vascular anomalies
Intracranial vascular lesions in up to 12% — risk of intracranial hemorrhage. Renal artery stenosis.
Up to 12%
Management & prognosis
💊
UDCA + fat-soluble vitamins A, D, E, K.
📊
Only ~24% survive to early adulthood with native liver.
✨
Maralixibat (ASBT inhibitor) — FDA-approved 2021 for pruritus in ALGS.
🫀
Liver transplant in ~25% of patients — excellent outcomes post-LT.
🩸
40% develop clinically evident portal hypertension by age 20.
9. Alpha-1-Antitrypsin Deficiency & Bile Acid Synthesis Defects
Alpha-1-antitrypsin deficiency
Caused by mutations in SERPINA1 (ZZ or SZ phenotype). The most common genetic liver disease (1 in 2,000–5,000 births). Misfolded A1AT protein accumulates in the hepatocyte ER → ER stress → liver injury and cirrhosis.
GGT
Often elevated. PAS+ diastase-resistant globules on liver biopsy (diagnostic).
Presentation
10–20% present with neonatal cholestasis. Acholic stools can mimic BA. Most cholestasis resolves by 4 months.
Diagnosis
Serum A1AT level is an acute-phase reactant — may be falsely normal in ill infants. Must check phenotype (Pi typing) as well.
Lung disease
Risk of early-onset emphysema in ZZ patients — a separate issue from liver disease.
Treatment
Supportive. No specific liver therapy approved. Liver transplant is curative (~7–17% develop cirrhosis requiring LT). Do NOT use A1AT augmentation therapy — it is for lung disease only.
Bile acid synthesis defects
A treatable group of disorders with a paradoxical lab pattern. Identifying them is critical because they respond dramatically to oral cholic acid.
Key clue
Low/normal GGT + LOW total serum bile acids (paradoxical!) — the most important diagnostic pattern.
Genes
HSD3B7, AKR1D1, CYP7B1, CYP7A1, BAAT, SLC27A5, AMACR, CYP27A1.
Mechanism
Defects in bile acid synthesis enzymes → accumulation of toxic intermediate bile acid species → liver damage.
Diagnosis
Urine bile acid fast-atom bombardment mass spectrometry (FABMS) — do this BEFORE starting UDCA (UDCA will elevate bile acids and confound results).
Treatment
Oral cholic acid (primary bile acid replacement). FDA-approved 2015. Normalizes liver function in most. Lifelong treatment required. Prevents cirrhosis.
Pitfall
UDCA does NOT treat bile acid synthesis defects — it can mask the diagnosis. Must confirm with FABMS first.
10. Other Key Metabolic Disorders Causing Cholestasis
Citrin deficiency (NICCD)
Gene: SLC25A13. Prevalent in East Asia. Cholestasis + hypercitrullinemia + high AFP + fatty liver. Most self-resolve by age 1. Tx: lactose-free MCT formula; carbohydrate restriction in later life. Some progress to cirrhosis needing LT. Clue: unexpected carbohydrate aversion (unlike other urea cycle defects).
Galactosemia
Gene: GALT. Detectable on newborn screen. Cholestasis + E. coli sepsis + cataracts + hypoglycemia + coagulopathy. Tx: galactose-free diet immediately. Early treatment prevents brain/liver injury. Clue: E. coli sepsis + jaundice in the first week of life = galactosemia until proven otherwise.
Tyrosinemia Type 1
Gene: FAH. High AFP, coagulopathy, renal tubular dysfunction, rickets. Risk of HCC. Tx: nitisinone (NTBC) + low tyrosine/phenylalanine diet. Start immediately. Clue: extreme coagulopathy out of proportion to other liver tests.
GALD (gestational alloimmune liver disease)
Formerly "neonatal hemochromatosis." Severe neonatal liver disease + extrahepatic siderosis. Maternal IgG-mediated fetal hepatocyte injury. Tx: exchange transfusion + IVIG postnatally. Maternal IVIG from 14 weeks gestation prevents recurrence in future pregnancies. Clue: severe coagulopathy + ALT/AST relatively low + high ferritin + low transferrin.
Panhypopituitarism
Hypoglycemia, adrenal insufficiency, micropenis. Non-fasting ultrasound needed (fasting causes severe hypoglycemia). MRI brain. Tx: hormone replacement (thyroid + cortisol + GH). Cholestasis resolves with correction of hormonal deficiency. Clue: persistent hypoglycemia + cholestasis + micropenis = panhypopituitarism until proven otherwise.
11. Parenteral Nutrition–Associated Cholestasis (PNAC)
Incidence climbs steeply with duration of PN:
Risk factors
Prematurity / low birth weight · PN > 2 weeks · soy-based lipid emulsions (phytosterols) · intestinal failure / short bowel syndrome · lack of enteral feeding / gut stimulation · recurrent central line infections · bacterial overgrowth and intestinal dysbiosis.
Prevention & treatment
🍼
Advance enteral feedings ASAP — even minimal feeds stimulate gallbladder emptying and gut hormones. Single most effective intervention.
💧
SMOF Lipid (mixed ILE) — soybean + MCT + olive + fish oil. Can give at 3 g/kg/day. May prevent PNAC.
🔁
Reduce / cycle PN — interrupt PN for a few hours per day. Minimize duration.
📉
Reduce soy lipid emulsion from 3 g/kg/day → 1 g/kg/day. Monitor for essential fatty acid deficiency.
🧼
Prevent central line infections — CLABSI directly contributes to IFALD. Meticulous line care and early PICC removal.
12. Diagnostic Algorithm & Management
Trigger: jaundice persisting > 2 weeks (term) OR direct bili > 1 mg/dL at any age.
Step 1 — History & physical exam
Directly observe stool color (not from history alone). Hepatomegaly, splenomegaly, abdominal exam. Cardiac murmur → Alagille, BA. Dysmorphic features → ALGS, chromosomal. Prenatal/perinatal/family history. Newborn screen results. Maternal infection history (TORCH). Consanguinity, siblings with liver disease.
Step 2 — Tier 1 laboratory workup
Total + direct bili, ALT, AST, GGT, ALP, albumin. PT/INR. CBC + differential. A1AT level AND phenotype (Pi typing). Blood + urine cultures (if febrile/ill). Glucose, ammonia, lactate, blood gas. Urine reducing substances (galactosemia). Newborn screen review or recheck. TORCH serology (IgG/IgM) in infant + mother. Fasting abdominal ultrasound.
⚡
URGENT: Refer to pediatric GI/hepatology for any confirmed conjugated hyperbilirubinemia — do not wait for the full workup to be complete.
Step 3 — Imaging & evaluate for BA
Fasting abdominal ultrasound
Triangular cord sign, abnormal/absent gallbladder, hepatic artery ratio, BASM features. Normal US does NOT rule out BA.
Liver biopsy
Bile duct proliferation, plugs, fibrosis → 90–95% sensitive for BA. Early biopsies may be non-specific.
Intraoperative cholangiogram
GOLD STANDARD. Non-visualization of biliary tree = BA. Kasai HPE done immediately if confirmed.
HIDA scintigraphy
Low specificity (33–80%). Reserve for preterm infants with low BA suspicion. Do not use as stand-alone test.
Step 4 — Extended metabolic & genetic testing
Low / normal GGT
PFIC gene panel (ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, MYO5B); urine bile acid FABMS.
Suspected CF
Sweat chloride or CFTR genotyping (some infants can't produce enough sweat).
Suspected endocrine
TSH + free T4, cortisol, GH, ACTH stimulation, brain MRI for pituitary.
Suspected metabolic
Urine organic acids, plasma amino acids, acylcarnitine profile, VLCFA.
Undiagnosed
Targeted gene panel (66+), WES or WGS — consider early for unexplained cases.
Step 5 — Management while diagnosis is being established
- MCT-containing formula (Pregestimil, Alimentum) or breast milk + MCT supplement. Target 125–140% of RDA calories.
- Fat-soluble vitamins A, D, E, K — supplemented and monitored serially.
- UDCA 10–30 mg/kg/day divided BID.
- Immunization review — see Section 14.
13. Nutritional Management & Medical Therapy
Fat-soluble vitamin supplementation
A (retinol)
Corneal/retinal damage, blindness
Aquasol A 5,000–25,000 IU/day PO
D (25-OH)
Rickets, bone fractures, hypocalcemia
Ergocalciferol 2,000–5,000 IU/day
E (α-tocopherol)
Peripheral neuropathy, hemolytic anemia, myopathy
TPGS d-α-tocopherol 25 IU/kg/day PO
K (phylloquinone)
Life-threatening coagulopathy, intracranial hemorrhage
Phytonadione 2.5–5 mg/day PO or parenteral
General nutritional principles
- Formula choice: MCT-containing formula (Pregestimil, Alimentum) or breast milk + MCT supplement. MCTs are absorbed directly from the small intestine without bile-acid solubilization.
- Caloric target: 125–140% of RDA based on ideal body weight. Cholestasis → malabsorption + increased metabolic demand = significantly higher needs.
- Route: oral preferred. If inadequate intake → NG drip feeds. PN only as last resort.
- Monitoring: serial vitamin A, D, E, K levels + INR. Weight, growth, head circumference. Triceps skinfold for body fat. Adjust doses to levels, not just age.
- Protein: unless hepatic encephalopathy is present, 2–4 g/kg/day is appropriate. Restriction is not routine in cholestasis without encephalopathy.
Medical therapies
UDCA (ursodeoxycholic acid)
First-line choleretic. Promotes bile flow, hepatoprotective, anti-apoptotic. Used in most cholestatic conditions except bile acid synthesis defects. 10–30 mg/kg/day divided BID.
Rifampicin
Pruritus unresponsive to UDCA. Induces hepatic enzymes → increases bile acid detoxification. Monitor LFTs. 10–20 mg/kg/day.
Cholestyramine
Bile acid–binding resin. Give 1–2 h BEFORE or AFTER other meds. 240 mg/kg/day in 3 divided doses (max 4 g/day < 10 yr).
Naltrexone
Opioid antagonist for refractory pruritus. May cause withdrawal-like symptoms initially. 1–2 mg/kg/day.
Sertraline
Pilot study: 75% improvement in pediatric cholestatic pruritus. 1–4 mg/kg/day.
IBAT inhibitors
(Maralixibat / Odevixibat)
Interrupt enterohepatic bile acid circulation. Maralixibat — FDA 2021 for ALGS pruritus. Odevixibat — for PFIC 2 pruritus.
🔬
On the horizon: FXR agonists (obeticholic acid — adult trials), nor-UDCA, gene therapy (PFIC 2/BSEP, A1AT), and RNA interference strategies for monogenic cholestatic diseases.
14. Disease-Specific Interventions & Immunizations
Disease-specific treatable causes
Biliary atresia
Kasai HPE
> 70% success < 60 days; < 25% after 90 days
Choledochal cyst
Mucosectomy + choledochoenterostomy
Malignancy risk if untreated; can delay past 6 mo / 5 kg if possible
Galactosemia
Galactose-free / lactose-free diet
Newborn screen — restrict immediately to prevent brain & liver injury
Tyrosinemia Type 1
Nitisinone (NTBC) + low-tyrosine diet
Start immediately. Dramatically reduces HCC risk and liver failure.
Hereditary fructose intolerance
Fructose- and sucrose-free diet
Recovery after withdrawal; prevention of progression
Hypothyroidism / panhypopituitarism
Thyroid hormone, cortisol, GH replacement
Cholestasis resolves with hormonal correction. Avoid fasting — hypoglycemia risk.
Bile acid synthesis defects
Oral cholic acid
FDA-approved 2015. Normalizes LFTs in most. Lifelong treatment.
Wolman disease (LAL deficiency)
Sebelipase alfa (ERT)
Approved for Wolman + CESD. Slows progression, improves survival.
UTI / sepsis-related cholestasis
Appropriate antibiotics / antiviral
Cholestasis often resolves with infection treatment
GALD
Exchange transfusion + IVIG
Maternal IVIG from 14 weeks gestation prevents recurrence
Immunizations in cholestatic infants
⚠️
The problem: < 20% of pediatric liver transplant recipients in the USA are up to date on age-appropriate immunizations at the time of transplant. 1 in 6 pediatric LT recipients is hospitalized with a vaccine-preventable infection in the first 5 years after transplantation.
✅
All routine vaccines on schedule. Don't delay.
💉
Hepatitis A and B — complete the series. Cannot be given post-transplant on immunosuppression.
⚡
Accelerate live vaccines if LT likely in year 1 — give MMR and Varicella at 6 months instead of 12.
🤒
Annual inactivated influenza vaccine. Safe pre- and post-transplant.
🚫
No live vaccines post-transplant — protect infants before transplant.
👨👩👧
Household contacts should also be vaccinated (cocooning strategy).
15. Emerging Screening & Biomarkers for Biliary Atresia
The challenge: USA median age at Kasai HPE remains 63 days. Three strategies are converging to bring that number down.
Newborn direct bilirubin screening
Harpavat et al. (JAMA 2020) showed conjugated bilirubin is elevated in BA infants within the first 72 hours of life. Sensitivity 100%, specificity 98.2% when direct bili > 0.3 mg/dL in the neonatal period. AAP already recommends universal total bilirubin screening before discharge — adding direct bilirubin appears feasible at low additional cost. Limitation: transcutaneous bilirubin devices cannot differentiate direct from indirect.
Infant stool color card programs
Taiwan introduced a stool color card in newborn health booklets in 2004. Parents report acholic stool; card reviewed at 1-month visit. Result: median age at HPE fell from 47 → 43 days; 5-year survival improved from 56% → 89%; jaundice-free rate at 3 months post-HPE improved from 49% → 66%. Mobile apps (PoopMD, PopoApp) use smartphone cameras for color recognition. The USA challenge is the lack of a standard 1-month well-child visit.
Serum MMP-7 (matrix metalloproteinase-7)
Biomarker of biliary epithelial injury identified by Lertudomphonwanit et al. (Sci Transl Med 2017): 95–98% sensitivity, 83–95% specificity for BA. Combined with GGT: AUC 0.98 for BA diagnosis. Limitation: no standardized cutoffs yet, not widely available commercially.
💰
Cost-effectiveness: a 20-year analysis showed stool color card screening would result in lower costs and better outcomes vs. no screening in the USA. Implementation is the main barrier.
16. Key Takeaways & Clinical Pearls
1️⃣Never assume. Conjugated bili > 1 mg/dL is never normal. Any jaundiced infant at 2 weeks: fractionate. Formula-fed = mandatory. Breastfed still jaundiced at 3 weeks = mandatory.
2️⃣BA infants appear healthy. They typically look well and feed normally. Don't be falsely reassured. Always directly observe stool color — acholic stool = urgent referral.
3️⃣Every day counts. Kasai HPE > 70% success if < 60 days; < 25% if > 90 days. USA median is 63 days. Urgent referral to pediatric hepatology saves native livers.
4️⃣GGT is your roadmap. Low/normal GGT + cholestasis → PFIC 1/2, bile acid synthesis defects. Low serum bile acids + cholestasis = bile acid synthesis defect → oral cholic acid.
5️⃣Treat everything. All cholestatic infants need MCT formula, vitamins A/D/E/K, UDCA, immunization review. If LT likely in year 1: give MMR + Varicella from 6 months.
6️⃣NGS is now routine. Gene panels, WES, WGS are affordable, fast, and cover 66+ genes. Consider early for unexplained cholestasis — may identify treatable conditions and avoid invasive tests.
7️⃣2022 AAP updated. Four nomograms by gestational age and risk factors. Race removed. Direct bili NOT subtracted from total. Higher thresholds for treatment.
8️⃣Screening is overdue. MMP-7 (95–98% sensitivity for BA), newborn direct bili screening, and stool color cards are promising strategies to bring age at HPE below 45 days.
17. Resident Self-Assessment
Question 1
A 4-month-old infant has cholestasis, severe pruritus and a surprisingly normal GGT. The most likely diagnosis is:
- A. Biliary atresia
- B. Alagille syndrome
- C. PFIC type 1 or 2 (Byler disease / BSEP deficiency)
- D. PFIC type 3 (MDR3 deficiency)
- E. Choledochal cyst
Show answer & explanation
Answer: C — PFIC type 1 or 2. Low/normal GGT + cholestasis is the hallmark of PFIC 1 & 2. GGT requires phospholipids in bile to be secreted. PFIC 1 (ATP8B1/FIC1) and PFIC 2 (ABCB11/BSEP) disrupt bile-acid transport but MDR3 remains intact — phospholipids are still present in bile, so GGT cannot be elevated. Biliary atresia, ALGS, and choledochal cyst all produce HIGH GGT via biliary obstruction. PFIC 3 (MDR3/ABCB4 defect) → absent phospholipids in bile → bile acids damage duct epithelium → HIGH GGT.
Low GGT differential: PFIC 1/2, PFIC 4 (TJP2), PFIC 5 (FXR/NR1H4), PFIC 6 (MYO5B), bile acid synthesis defects (treat with oral cholic acid!), GALD.
Question 2
A toddler presents with cholestasis, growth failure, triangular facies, butterfly vertebrae, posterior embryotoxon and peripheral pulmonary stenosis. The most likely diagnosis is:
- A. Alpha-1-antitrypsin deficiency
- B. Alagille syndrome (JAG1 / NOTCH2 mutation)
- C. PFIC type 1
- D. Wilson disease
- E. Biliary atresia
Show answer & explanation
Answer: B — Alagille syndrome. The question lists all five features of the Alagille pentad: triangular facies, butterfly vertebrae (~39%), posterior embryotoxon (~43%), peripheral pulmonary stenosis (~88%), and bile duct paucity with cholestasis.
A1AT deficiency shows PAS+ globules with no dysmorphic features. PFIC type 1 = low GGT + diarrhea + hearing loss, no skeletal/ocular/cardiac features. Wilson disease presents after age 5 with neuropsychiatric signs and Kayser-Fleischer rings. Biliary atresia is not associated with dysmorphic facies, vertebral, or ocular anomalies (BASM has splenic/cardiac defects but not the Alagille pentad).
Question 3
A 6-week-old has persistent jaundice, acholic stools, hepatomegaly and markedly elevated GGT. Fasting ultrasound shows no gallbladder. The most likely diagnosis and most important next step are:
- A. Neonatal hepatitis — observe and repeat labs
- B. Biliary atresia — proceed to liver biopsy then intraoperative cholangiogram ± Kasai HPE
- C. Alagille syndrome — cardiac evaluation only
- D. Choledochal cyst — ERCP
- E. CMV hepatitis — start ganciclovir
Show answer & explanation
Answer: B — Biliary atresia; liver biopsy → IOC → Kasai HPE. Absent gallbladder on fasting ultrasound has very high PPV for biliary atresia. The presentation — jaundice at 6 weeks, acholic stools, hepatomegaly, markedly elevated GGT, absent gallbladder — is classic. Immediate surgical workup is mandatory.
Management sequence: liver biopsy (bile duct proliferation, portal fibrosis, bile plugs) → intraoperative cholangiogram (gold standard) → Kasai HPE in the same operation if confirmed.
Why timing matters: Kasai success > 70% before 60 days; < 25% after 90 days. USA median is 63 days. Every week of delay costs native liver survival. Observation, cardiac-only evaluation, ERCP, or antiviral therapy are all inappropriate here.
References & Sources
- Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant ≥35 Weeks Gestation. Pediatrics. 2022;150(3):e2022058859.
- Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of NASPGHAN and ESPGHAN. J Pediatr Gastroenterol Nutr. 2017;64(1):154–168.
- Feldman AG, Sokol RJ. Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics. Nat Rev Gastroenterol Hepatol. 2019;16(6):346–360.
- Feldman AG, Sokol RJ. Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention. NeoReviews. 2021;22(12):e819–e830.
- Ranucci G, Della Corte C, Alberti D, et al. Diagnostic approach to neonatal and infantile cholestasis: A position paper by the SIGENP liver disease working group. Dig Liver Dis. 2022;54:40–53.
- Catzola A, Vajro P. Management options for cholestatic liver disease in children. Expert Rev Gastroenterol Hepatol. 2017;11(11):1019–1030.
- Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic yield of newborn screening for biliary atresia using direct or conjugated bilirubin measurements. JAMA. 2020;323(12):1141–1150.
- Lertudomphonwanit C, Mourya R, Fei L, et al. Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia. Sci Transl Med. 2017;9(417):eaan8462.
- Serinet M-O, Wildhaber BE, Broué P, et al. Impact of age at Kasai operation on its results in late childhood and adolescence. Pediatrics. 2009;123(5):1280–1286.
- Chardot C, Buet C, Serinet M-O, et al. Improving outcomes of biliary atresia: French national series 1986–2009. J Hepatol. 2013;58(6):1209–1217.
- Lien T-H, Chang M-H, Wu J-F, et al. Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology. 2011;53(1):202–208.
- Feldman AG, Sundaram SS, Beaty BL, et al. Immunization status at the time of liver transplant in children. JAMA. 2019;322(18):1822–1824.
Further resources: NASPGHAN (naspghan.org) · AAP (aap.org) · ChiLDReN Network (childrennetwork.org) · SIGENP (sigenp.it)
SJ
Dr. Shahid Javaid
Board-Certified Pediatric Gastroenterologist & Founder, SJ Formula Hub
Dr. Javaid is a pediatric gastroenterologist with clinical expertise in neonatal cholestasis, infant nutrition, cow's milk protein allergy, and gastrointestinal feeding disorders. SJ Formula Hub provides evidence-based references for parents and clinicians navigating pediatric nutrition and hepatobiliary disease.
Disclaimer: This article is intended as an educational resource for pediatric residents, trainees, and clinicians. It is not a substitute for institutional protocols, attending judgment, or up-to-date guideline review. Recommendations should be applied in the context of individual patient circumstances and current local practice.